SCHEMBL1543064

SCHEMBL1543064

NCC1C(=O)Nc2ccc(F)cc21

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 7/20 0.51
DRD2 P14416 1/20 0.49
DRD1 P21728 1/20 0.49
HTR2A P28223 1/20 0.49
HTR2C P28335 1/20 0.49
ADRA1A P35348 1/20 0.49
HTR6 P50406 1/20 0.49
HDAC1 Q13547 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
IDO1 P14902 1/20 0.46
PGR P06401 1/20 0.40
TP53 P04637 2/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
NQO2 P16083 2/20 0.39
GSK3B P49841 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2201343 0.88 HTR7 (0.59) HTR7DRD2DRD1HTR2AHTR2C
SCHEMBL2988221 0.85 PGR (0.56) HTR7DRD2DRD1HTR2AHTR2C
SCHEMBL18854022 0.85 PGR (0.56) HTR7DRD2DRD1HTR2AHTR2C
SCHEMBL2332233 0.83 HTR7 (0.46) HTR7DRD2DRD1HTR2AHTR2C
SCHEMBL9651965 0.82 HTR7 (0.54) HTR7DRD2DRD1HTR2AHTR2C
SCHEMBL14996404 0.82 HTR7 (0.54) HTR7DRD2DRD1HTR2AHTR2C
SCHEMBL8138050 0.81 HTR7 (0.48) HTR7DRD2DRD1HTR2AHTR2C
SCHEMBL12225622 0.79 HTR7 (0.51) HTR7DRD2DRD1HTR2AHTR2C
SCHEMBL1455904 0.79 HTR7 (0.60) HTR7DRD2DRD1HTR2AHTR2C
SCHEMBL15450810 0.77 HDAC1 (0.56) HTR7DRD2DRD1HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110306597-A1 Nicotinamide Derivatives CRAWFORTH JAMES MICHAEL (GB) 2011-12-15 US disclosed
EP-1613368-B1 CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2011-11-30 EP disclosed
EP-2307378-A1 NICOTINAMIDE DERIVATIVES Pfizer Limited (GB) 2011-04-13 EP disclosed
WO-2009153721-A1 NICOTINAMIDE DERIVATIVES PFIZER LIMITED (GB) 2009-12-23 WO disclosed
US-7288559-B2 Carboxamide spirohydantoin CGRP receptor antagonists MERCK + CO, INC. (US) 2007-10-30 US disclosed
US-7288559-B2 Carboxamide spirohydantoin CGRP receptor antagonists MERCK + CO, INC. (US) 2007-10-30 US disclosed
US-20070111982-A1 Calcitonin Gene-Related Peptide, CGRP; treatment of migraine and cluster headache; 2,5-dioxo-3',4'-dihydro-spiro(imidazolidine-4,2'(1'H)-naphthalene)-6'-carboxamides MERCK SHARP & DOHME LLC 2007-05-17 US disclosed
US-20070111982-A1 Calcitonin Gene-Related Peptide, CGRP; treatment of migraine and cluster headache; 2,5-dioxo-3',4'-dihydro-spiro(imidazolidine-4,2'(1'H)-naphthalene)-6'-carboxamides MERCK SHARP & DOHME LLC 2007-05-17 US disclosed
WO-2003035615-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306597-A1 Nicotinamide Derivatives NNT, NAMPT, NQO1 HTR7 2107/4885DRD2 2161/4885DRD1 2302/4885
US-20070111982-A1 Calcitonin Gene-Related Peptide, CGRP; treatment of migraine and cluster headache; 2,5-dioxo-3',4'-dihydro-spiro(imidazolidine-4,2'(1'H)-naphthalene)-6'-carboxamides CALCA, CALCRL, CALCB HTR7 281/4885DRD2 1053/4885DRD1 1235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.